Skip to main content
    E

    Edgewise Therapeutics Inc (EWTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $43.68
    -2.25 (-4.90%)

    Market Cap: $5.03B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Edgewise Therapeutics Inc (EWTX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 4, 2026. Financial statements from company filings, amounts in US dollars.

    Edgewise Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$167.79M, operating cash flow was -$143.82M and free cash flow was -$144.07M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of $1.17B.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $191.41M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Cost of revenue$0$0$0$0$0$0$123.00K
    Gross profit$0$0$0$0$0$0-$123.00K
    Research and development$151.39M$126.97M$90.91M$54.03M$32.19M$14.98M$8.62M
    Operating income-$191.41M-$158.83M-$114.36M-$71.66M-$43.22M-$17.19M-$9.92M
    Net income-$167.79M-$133.81M-$100.16M-$67.64M-$42.81M-$17.12M-$9.49M
    EBITDAN/AN/AN/AN/A-$42.94M-$17.01M-$9.80M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$2.12M$0$0$0$2.25M
    Gross profit$0$0$0N/A$0$0$0$1.06M$0$0$0$1.72M
    Operating income-$46.14M-$61.94M-$54.12M-$55.98M-$46.86M-$42.61M-$45.96M-$45.54M-$40.43M-$38.11M-$34.75M-$33.86M
    Net income$1.17B-$57.33M-$49.01M-$50.22M-$40.67M-$36.12M-$40.80M-$39.66M-$34.13M-$31.50M-$28.52M-$30.14M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $1.01M by $60.13M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$552.60M$486.82M$340.04M$367.10M$285.23M$131.14M$24.54M
    Current assets$543.38M$475.48M$327.00M$357.00M$283.77M$129.65M$24.04M
    Cash and equivalents$61.15M$41.67M$86.10M$21.99M$15.57M$104.92M$23.65M
    Total liabilities$30.35M$27.60M$21.20M$20.39M$10.85M$4.34M$41.39M
    Short-term debt$1.01M$996.00K$980.00K$608.00KN/AN/AN/A
    Shareholder equity$522.26M$459.22M$318.83M$346.72M$274.38M-$33.42M-$16.85M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.78B$479.69M$518.52M$552.60M$583.47M$613.33M$454.39M$486.82M$511.28M$531.65M$553.81M$340.04M
    Total liabilities$147.35M$31.61M$25.32M$30.35M$24.82M$24.26M$24.67M$27.60M$22.41M$21.17M$18.86M$21.20M
    Cash and equivalents$68.68M$72.32M$33.21M$61.15M$46.00M$43.40M$49.92M$41.67M$44.81M$43.48M$30.26M$86.10M
    Shareholder equity$1.63B$448.08M$493.20M$522.26M$558.65M$589.07M$429.72M$459.22M$488.88M$510.47M$534.94M$318.83M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$143.82M-$109.03M-$91.95M-$52.63M-$33.51M-$14.63M-$9.17M
    Capital expenditures$256.00K$1.31M$5.75M$5.55M$668.00K$203.00K$180.00K
    Free cash flow-$144.07M-$110.34M-$97.69M-$58.18M-$34.17M-$14.84M-$9.35M
    Share repurchasesN/AN/AN/AN/A$124.00K$0N/A
    Investing cash flow-$32.79M-$184.66M$102.89M-$70.58M-$242.23M-$24.38M-$180.00K
    Financing cash flow$196.09M$249.25M$53.17M$129.64M$186.38M$120.28M$24.80M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$78.29M-$42.47M-$42.54M-$38.59M-$34.78M-$32.58M-$37.87M-$26.96M-$27.37M-$26.10M-$28.60M-$26.83M
    Capital expenditures$17.00K$32.00K$260.00K$73.00K$89.00K$50.00K$44.00K$70.00K$1.13M$28.00K$144.00K$161.00K
    Free cash flow-$78.31M-$42.50M-$42.80M-$38.66M-$34.87M-$32.63M-$37.91M-$27.03M-$28.50M-$26.13M-$28.74M-$26.99M
    Last 12 quarters

    Frequently Asked Questions About EWTX

    What is Edgewise Therapeutics' annual revenue?

    Edgewise Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Edgewise Therapeutics profitable?

    No. Edgewise Therapeutics reported net income of -$167.79M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does EWTX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$143.82M minus capital expenditures of $256.00K produced free cash flow of -$144.07M.

    How much debt does Edgewise Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $1.01M and cash and equivalents of $61.15M.